Rhododenol-induced Leukoderma
Conditions
Interventions
Bimatoprost would be applied on the target region once a day before bed time. The dose increase would be considered to twice a day (morning after cleansing and before bed time) after three months app
Sponsors
Teikyo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients diagnosed as Rhododenol-induced Leukoderma according to diagnostic criteria of Japanese Dermatology Association (meeting all contents of essential diagnostic criteria and meeting at least one content of minor diagnostic criteria) a)essential diagnostic criteria i)Used Rhododenol containing cosmetics ii)Not having Leukoderma before using Rhododenol containing cosmetics. Complete or incomplete depigmented area emerged after use of Rhododenol containing cosmetics on mostly Rhododenol applied area. b)Minor diagnostic criteria i)The enlargement of Leukoderma stopped within a month after withdrawal of Rhododenol containing cosmetics. ii)After withdrawal of Rhododenol containing cosmetics, at least part of Leukoderma became re-pigmented. 2)All participants are fully explained about the aim, content and expected side effects of the study. After confirming the participants' understanding, written informed consent is taken under their free will.
Exclusion criteria
Exclusion criteria: 1)Age under twenty years old at the time of informed consent. 2)Those who were suspected of concomitant vitiligo vulgaris. 3)Those who show skin problems such as erythema at the site of target region. 4)Those who show allagic reaction against Bimatoprost. 5)Those women who are pregnant or possibly pregnant or during lactation or those who cannot agree with contraception during the study. 6)Those otherwise principal physician considered unsuitable to include in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of pigmentation after six months application of Bimatoprost on target region | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The difference of six months from baseline as for, 1)Physician's evaluations on target region 2)Colorimeter values 3)Leukoderma sizes 2.Comparison between treated area and control area. | — |
Countries
Japan
Contacts
Public ContactShinichi Watanabe
Teikyo University School of Medicine Department of Dermatology
Outcome results
None listed